Clinical trial registry record

A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Withdrawn.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 5, 2019.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02873351
Last registry update
April 5, 2019
Status
Withdrawn
Phase
Phase 2
Sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Enrollment
0
Countries
United States
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
Evidence population
Human clinical study registration
Participants
0
Population
ALL · 50 Years to 85 Years
Duration
2019-09-01 to 2020-12-01
Intervention
carbidopa-levodopa 25-100 mg; placebo for carbidopa-levodopa 25-100 mg
Comparator
Placebo for carbidopa-levodopa 25-100 mg
Outcomes measured
Treatment Emergent Adverse Events — 90 +- 10 days; Change from Baseline in Best Corrected Visual Acuity — 45 +/- 5 days and 90 +/- 10 days; Change from Baseline in Low Light Visual Acuity — 45 +/- 5 days and 90 +/- 10 days; Change from Baseline in Dark Adaptation — 45 +/- 5 days and 90 +/- 10 days; Change from Baseline in Low Luminance Questionnaire Scores — 45 +/- 5 days and 90 +/- 10 days; Change from Baseline in Optical Coherence Tomography — 45 +/- 5 days and 90 +/- 10 days
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON